Literature DB >> 33291622

Type I Interferon Signature in Chilblain-Like Lesions Associated with the COVID-19 Pandemic.

Roland Aschoff1, Nick Zimmermann1, Stefan Beissert1, Claudia Günther1.   

Abstract

Contemporarily to the new SARS-CoV-2 mediated COVID-19 pandemic, a rise in patients with acral chilblain lesions has been described. They manifest late after mild disease or asymptomatic exposure to SARS-CoV-2. Their pathogenic evolution is currently unknown. In biopsies from three patients with acral partially ulcerating chilblain lesions that occurred associated to the COVID-19 pandemic, we analysed the expression of type I interferon induced proteins and signal transduction kinases. Histology demonstrated perivascular and periadnexal lymphohistiocytic infiltrates and endothelial dominated MxA-staining, as well as pJAK1 activation. Our findings demonstrate induction of the type I IFN pathway in lesional sections of COVID-19-associated chilblain-like lesions. This may indicate a local antiviral immune activation status associated with preceding exposure to SARS-CoV-2.

Entities:  

Keywords:  SARS-CoV-2; chilblain; type I interferon

Year:  2020        PMID: 33291622      PMCID: PMC7768511          DOI: 10.3390/dermatopathology7030010

Source DB:  PubMed          Journal:  Dermatopathology (Basel)        ISSN: 2296-3529


  22 in total

1.  Focus on "COVID Toes".

Authors:  Claudia Hernandez; Anna L Bruckner
Journal:  JAMA Dermatol       Date:  2020-09-01       Impact factor: 10.282

Review 2.  The Type I Interferonopathies.

Authors:  Min Ae Lee-Kirsch
Journal:  Annu Rev Med       Date:  2016-11-02       Impact factor: 13.739

3.  Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.

Authors:  Nick Zimmermann; Christine Wolf; Reiner Schwenke; Anne Lüth; Franziska Schmidt; Kerstin Engel; Min Ae Lee-Kirsch; Claudia Günther
Journal:  JAMA Dermatol       Date:  2019-03-01       Impact factor: 10.282

4.  Evaluation of Chilblains as a Manifestation of the COVID-19 Pandemic.

Authors:  Anne Herman; Caroline Peeters; Alexia Verroken; Isabelle Tromme; Dominique Tennstedt; Liliane Marot; Claire Dachelet; Damien Gruson; Cedric Hermans; Marie Baeck
Journal:  JAMA Dermatol       Date:  2020-09-01       Impact factor: 10.282

5.  Familial chilblain lupus due to a novel mutation in the exonuclease III domain of 3' repair exonuclease 1 (TREX1).

Authors:  Claudia Günther; Nicole Berndt; Christine Wolf; Min Ae Lee-Kirsch
Journal:  JAMA Dermatol       Date:  2015-04       Impact factor: 10.282

6.  Cutaneous manifestations in COVID-19: a first perspective.

Authors:  S Recalcati
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-05       Impact factor: 6.166

7.  Coronavirus (COVID-19) infection-induced chilblains: A case report with histopathologic findings.

Authors:  Athanassios Kolivras; Florence Dehavay; Daphné Delplace; Francesco Feoli; Isabelle Meiers; Laurenzo Milone; Catherine Olemans; Ursula Sass; Anne Theunis; Curtis T Thompson; Laura Van De Borne; Bertrand Richert
Journal:  JAAD Case Rep       Date:  2020-04-18

8.  Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.

Authors:  Mandeep R Mehra; Sapan S Desai; SreyRam Kuy; Timothy D Henry; Amit N Patel
Journal:  N Engl J Med       Date:  2020-05-01       Impact factor: 91.245

9.  Characterization of acute acral skin lesions in nonhospitalized patients: A case series of 132 patients during the COVID-19 outbreak.

Authors:  Diego Fernandez-Nieto; Juan Jimenez-Cauhe; Ana Suarez-Valle; Oscar M Moreno-Arrones; David Saceda-Corralo; Arantxa Arana-Raja; Daniel Ortega-Quijano
Journal:  J Am Acad Dermatol       Date:  2020-04-24       Impact factor: 11.527

10.  Cutaneous autoimmune diseases during COVID-19 pandemic.

Authors:  C Günther; R Aschoff; S Beissert
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-07-02       Impact factor: 9.228

View more
  10 in total

1.  Type I Interferon Signature in Chilblains Following SARS-CoV-2 mRNA Vaccine: A Case Report.

Authors:  Karim Souaid; Bénédicte Oulès; Pierre Sohier; Lydia Deschamps; Sélim Aractingi; Nicolas Dupin
Journal:  Acta Derm Venereol       Date:  2021-11-10       Impact factor: 3.875

2.  Long-term Outcome of Chilblains Associated with SARS-CoV-2.

Authors:  Florence Poizeau; Sébastien Barbarot; Yannick Le Corre; Emilie Brenaut; Mahtab Samimi; Hélène Aubert; Alexis Toubel; Alain Dupuy
Journal:  Acta Derm Venereol       Date:  2021-12-13       Impact factor: 3.875

3.  Frequency of relapse and persistent cutaneous symptoms after a first episode of chilblain-like lesion during the COVID-19 pandemic.

Authors:  P Moghadam; L Frumholtz; L Jaume; A De Masson; M Jachiet; E Begon; L Sulimovic; A Petit; H Bachelez; M Bagot; J-D Bouaziz; C Cassius
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-06-19       Impact factor: 9.228

Review 4.  COVID-19 and the peripheral nervous system. A 2-year review from the pandemic to the vaccine era.

Authors:  Arens Taga; Giuseppe Lauria
Journal:  J Peripher Nerv Syst       Date:  2022-03-14       Impact factor: 5.188

5.  Chilblain-Like Lesions during COVID-19 Pandemic: The State of the Art.

Authors:  Andrea Bassi; Teresa Russo; Giuseppe Argenziano; Carlo Mazzatenta; Elisabetta Venturini; Iria Neri; Vincenzo Piccolo
Journal:  Life (Basel)       Date:  2021-01-02

6.  Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak.

Authors:  L Frumholtz; J-D Bouaziz; M Battistella; J Hadjadj; R Chocron; D Bengoufa; H Le Buanec; L Barnabei; S Meynier; O Schwartz; L Grzelak; N Smith; B Charbit; D Duffy; N Yatim; A Calugareanu; A Philippe; C L Guerin; B Joly; V Siguret; L Jaume; H Bachelez; M Bagot; F Rieux-Laucat; S Maylin; J Legoff; C Delaugerre; N Gendron; D M Smadja; C Cassius
Journal:  Br J Dermatol       Date:  2021-10-05       Impact factor: 11.113

7.  Dermatology and COVID-19: The Hidden Pandemic.

Authors:  S Recalcati; G Nazzaro
Journal:  J Clin Med       Date:  2022-07-28       Impact factor: 4.964

8.  Course and outcome of chilblain-like acral lesions during COVID-19 pandemic.

Authors:  Kristin Blau; Sophia Lehr; Roland Aschoff; Suzan Al Gburi; Normi Brück; Maria Chapsa; Anja Schnabel; Susanne Abraham; Korinna Jöhrens; Stefan Beissert; Claudia Günther
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-09-23       Impact factor: 9.228

9.  COVID-19 pandemic-associated chilblains: more links for SARS-CoV-2 and less evidence for high interferon type I systemic response.

Authors:  Didier Bessis; Sophie Trouillet-Assant; Léo-Paul Secco; Nathalie Bardin; Brigitte Blanc; Véronique Blatière; Christine Chable-Bessia; Christophe Delfour; Céline Girard; Jean-Christophe Richard; Nathalie Gros; Vincent Le Moing; Nicolas Molinari; Valérie Pallure; Amandine Pisoni; Nadia Raison-Peyron; Elisa Reynaud; Émilie Schwob; Rémi Pescarmona; Quentin Samaran; Marjolaine Willems; Thierry Vincent; Mircea T Sofonea; Alexandre Belot; Édouard Tuaillon
Journal:  Br J Dermatol       Date:  2022-08-16       Impact factor: 11.113

Review 10.  A clinicopathological description of COVID-19-induced chilblains (COVID-toes) correlated with a published literature review.

Authors:  Athanassios Kolivras; Curtis Thompson; Ievgenia Pastushenko; Marisa Mathieu; Pascal Bruderer; Marine de Vicq; Francesco Feoli; Saadia Harag; Isabelle Meiers; Catherine Olemans; Ursula Sass; Florence Dehavay; Ali Fakih; Xuan-Lan Lam-Hoai; Alice Marneffe; Laura Van De Borne; Valerie Vandersleyen; Bertrand Richert
Journal:  J Cutan Pathol       Date:  2021-08-09       Impact factor: 1.458

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.